Back to top

Analyst Blog

Orthopedic implant devices maker Exactech (EXAC - Snapshot Report) reported preliminary sales for the fourth quarter and fiscal 2011. The Gainesville-based company expects to register revenues of $53.1 million in the fourth quarter, a year-over-year growth of 2.5%.

For the full year, the company expects to rake in sales of $205.4 million, an 8% annualized increase. Revenues for both the periods were essentially in line with the Zacks Consensus Estimates.

Exactech noted that its domestic sales for the year grew 1% to $133 million while overseas revenues soared 24% to $72.4 million. U.S. revenues for the quarter fell 2% to $34 million while international revenues surged 11% to $19.1 million.  

Per the preliminary results, revenues from the company’s larger knee implant business dipped 2% to $20.1 million in the fourth quarter. Extremities implant sales spiked 29% to $11 million. Revenues from hip implant franchise climbed 13% to $9.3 million while biologic and spine sales tumbled 21% to $5.9 million. Exactech will report its fourth quarter and full year 2011 results on February 28.  

Moving ahead, Exactech expects revenues for fiscal 2012 in the range of $215 million to $223 million. Earnings per share (as reported) for the year are expected in the band of 88 cents to 96 cents. The corresponding Zacks Consensus Estimates are $216 million and 97 cents, respectively.

For the first quarter, Exactech sees earnings per share in the range of 22 cents to 24 cents on revenues between $54 million and $57 million. Analysts polled by Zacks currently expect revenues of $56 million and earnings of 26 cents a share on an average for the first quarter.

Exactech develops and markets orthopedic implant devices. Its orthopedic products are utilized for the restoration of bones and joints that have degenerated due to diseases. Apart from the U.S. the company markets its products in more than 30 other markets globally.

Exactech competes with the likes of  Wright Medical (WMGI - Analyst Report), Stryker (SYK - Analyst Report), Johnson & Johnson (JNJ - Analyst Report) and Zimmer Holdings (ZMH - Analyst Report), some of whom are much larger in terms of size and resources.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%
STRATTEC SE… STRT 80.24 +3.00%